Research ExplorerPublicationsAdjuvant pembrolizumab-related hyperprogression in stage III...

Adjuvant pembrolizumab-related hyperprogression in stage III melanoma

Standard

Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. / Ammann, Nadine L; Geidel, Glenn; Schneider, Stefan W; Gebhardt, Christoffer.

In: J DTSCH DERMATOL GES, Vol. 19, No. 9, 09.2021, p. 1341-1345.

Research output: SCORING: Contribution to journal › Letter › Research › peer-review

Harvard

Ammann, NL, Geidel, G, Schneider, SW & Gebhardt, C 2021, 'Adjuvant pembrolizumab-related hyperprogression in stage III melanoma', J DTSCH DERMATOL GES, vol. 19, no. 9, pp. 1341-1345. https://doi.org/10.1111/ddg.14535

APA

Ammann, N. L., Geidel, G., Schneider, S. W., & Gebhardt, C. (2021). Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. J DTSCH DERMATOL GES, 19(9), 1341-1345. https://doi.org/10.1111/ddg.14535

Vancouver

Ammann NL, Geidel G, Schneider SW, Gebhardt C. Adjuvant pembrolizumab-related hyperprogression in stage III melanoma. J DTSCH DERMATOL GES. 2021 Sep;19(9):1341-1345. https://doi.org/10.1111/ddg.14535

Bibtex

@article{b3404916c83e4e5a95cfad0d823fa71b,
title = "Adjuvant pembrolizumab-related hyperprogression in stage III melanoma",
keywords = "Antibodies, Monoclonal, Humanized/adverse effects, Humans, Melanoma/drug therapy, Neoplasm Staging, Skin Neoplasms/drug therapy",
author = "Ammann, {Nadine L} and Glenn Geidel and Schneider, {Stefan W} and Christoffer Gebhardt",
year = "2021",
month = sep,
doi = "10.1111/ddg.14535",
language = "English",
volume = "19",
pages = "1341--1345",
journal = "J DTSCH DERMATOL GES",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - Adjuvant pembrolizumab-related hyperprogression in stage III melanoma

AU - Ammann, Nadine L

AU - Geidel, Glenn

AU - Schneider, Stefan W

AU - Gebhardt, Christoffer

PY - 2021/9

Y1 - 2021/9

KW - Antibodies, Monoclonal, Humanized/adverse effects

KW - Humans

KW - Melanoma/drug therapy

KW - Neoplasm Staging

KW - Skin Neoplasms/drug therapy

U2 - 10.1111/ddg.14535

DO - 10.1111/ddg.14535

M3 - Letter

C2 - 34255418

VL - 19

SP - 1341

EP - 1345

JO - J DTSCH DERMATOL GES

JF - J DTSCH DERMATOL GES

SN - 1610-0379

IS - 9

ER -